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Abstract
Background: Polymorphisms in chemokine (C-C motif) receptors 2 and 5 genes (CCR2 and CCR5) have been
associated with HIV-1 infection and disease progression. We investigated the impact of CCR2-CCR5 haplotypes on
HIV-1 viral load (VL) and heterosexual transmission in an African cohort. Between 1995 and 2006, cohabiting
Zambian couples discordant for HIV-1 (index seropositive and HIV-1 exposed seronegative {HESN}) were monitored
prospectively to determine the role of host genetic factors in HIV-1 control and heterosexual transmission.
Genotyping for eight CCR2 and CCR5 variants resolved nine previously recognized haplotypes. By regression and
survival analytic techniques, controlling for non-genetic factors, we estimated the effects of these haplotypic
variants on a) index partner VL, b) seroconverter VL, c) HIV-1 transmission by index partners, d) HIV-1 acquisition by
HESN partners.
Results: Among 567 couples, 240 virologically linked transmission events had occurred through 2006. HHF*2
homozygosity was associated with significantly lower VL in seroconverters (mean beta = -0.58, log10 P = 0.027) and
the HHD/HHE diplotype was associated with significantly higher VL in the seroconverters (mean beta = 0.54, log10
P = 0.014) adjusted for age and gender in multivariable model. HHD/HHE was associated with more rapid
acquisition of infection by the HESNs (HR = 2.0, 95% CI = 1.20-3.43, P = 0.008), after adjustments for index partner
VL and the presence of genital ulcer or inflammation in either partner in Cox multivariable models. The HHD/HHE
effect was stronger in exposed females (HR = 2.1, 95% CI = 1.14-3.95, P = 0.018).
Conclusions: Among Zambian discordant couples, HIV-1 coreceptor gene haplotypes and diplotypes appear to
modulate HIV-1 VL in seroconverters and alter the rate of HIV-1 acquisition by HESNs. These associations replicate
or resemble findings reported in other African and European populations.
Background
Sub-Saharan Africa is home to about 10% of the world’s
population but bears nearly 64% of all HIV-1 infections
[1], with most HIV-1 transmission occurring hetero-
sexually. In Zambia, about one in five cohabiting cou-
ples involves an HIV-1 seropositive (index) and a
seronegative (exposed) partner; these serodiscordant
couples are at high risk of heterosexual transmission,
with an estimated rate of eight transmission events per
100 person-years of follow-up [2].
The rate of within-couple heterosexual HIV-1 trans-
mission is highly variable, and a number of viral, host
and environmental factors may modify transmission
(infectiousness), acquisition (susceptibility) or both [3].
Donor HIV-1 viral load (VL), age, sex, history of sexu-
ally transmitted infection (STI), unprotected sex, and
possible HIV-1 subtype are among the major factors
implicated [4,5]. In southern Africa, unusual biological
features of the predominant C subtype of HIV-1 [5] and
absence of the human CC chemokine receptor 5 gene
(CCR5) 32-bp deletion (Δ32) as a resistance factor may
contribute to relatively high transmission rate.
The recognition that Caucasians who are homozygous
for CCR5-Δ32 are highly resistant to HIV-1 infection
* Correspondence: rakhi_shai@uab.edu; lyhu@uab.edu
1Department of Epidemiology University of Alabama at Birmingham (UAB),
Birmingham, AL, USA
Full list of author information is available at the end of the article
Malhotra et al. Retrovirology 2011, 8:22
http://www.retrovirology.com/content/8/1/22
© 2011 Malhotra et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.was a landmark finding in research on HIV-1 transmis-
sion [6-9]. It stimulated a concerted effort to elucidate
the impact of other genetic variations in CCR5 and the
adjacent gene CCR2 on HIV-1 transmission and disease
progression [10-12]. Research on the association of
these variants with transmission has been largely cross-
sectional or retrospective; the few prospective studies
have focused on vertical (mother-to-child) transmission
[13] and on HIV-1 exposed seronegatives (HESNs), in
part because of the difficulty in enrolling and following
HIV-1-discordant couples.
In Zambia, thousands of cohabiting and HIV-1 discor-
dant couples have been offered voluntary counseling
and testing (VCT) services since 1995 [2], and some of
them have been followed for more than 10 years [14].
Despite counseling and behavioral interventions, the
rate of HIV-1 transmission among these couples has
remained high [15]. This circumstance permitted us to
investigate the association of polymorphism in CCR2
and CCR5 with heterosexual transmission of phylogen-
etically related [16] HIV-1 within discordant partners.
The major published studies [11,13,17-20] examining
the effects of CCR2 and CCR5 SNPs/haplotypes/diplo-
types on HIV-1 infection or disease progression have
shown a wide spectrum of effects in various populations
(See Additional File 1; Table S1). We systematically
tested hypotheses on these as well as other markers that
occurred frequently enough in our population to permit
meaningful inferences, especially in confirmation of ear-
lier findings.
Results
General characteristics of Zambian couples with linked
HIV-1 viruses
During the study period 567 couples were eligible for
analysis. Linked transmission occurred in 240 of the
567; (Table 1). nearly all (> 95%) of the HIV-1
sequences from these transmission pairs corresponded
to viral subtype C (HIV-1C) [16]. Male-to-female trans-
mission accounted for nearly three-fifths of the incident
infections (Table 1). The younger age of exposed
women and, to a lesser extent, exposed men was asso-
ciated with seroconversion. Certain non-genetic charac-
teristics of the partners were also independently
associated with increased transmission: genital ulcers or
genital inflammation in any partner (HR = 3.62, 95% CI:
2.65-4.93, P < 0.0001) and high VL in the index partner
(HR = 1.59, 95% CI: 1.32-1.91, P < 0.0001). These fac-
tors were retained in subsequent models that tested the
impact of genetic markers.
Distribution of CCR2-CCR5 haplotypes in Zambian couples
Eight CCR2-CCR5 haplotypes were observed in the fre-
quency distribution shown in Table 2. Nearly 50% of all
haplotypes were HHA or HHF*2. Haplotype HHB was
rarely seen, and the Δ32-containing haplotype HHG*2
was not observed at all. The most common genotypes
(diplotypes) were HHA/HHF*2, HHA/HHD, HHA/
HHA, HHA/HHE, HHD/HHF*2, and HHE/HHF*2 (See
Additional File 2; Table S2). The overall distribution of
CCR2-CCR5 haplotypes did not conform to HWE
(Table 2). After stratification of the cohort into trans-
mission and nontransmission index partners, serocon-
verters, and exposed uninfected partners, the haplotype
distribution deviated significantly from HWE in all three
seropositive groups, but not in the HESNs.
CCR2-CCR5 determinants of VL
Although HHA and HHC have previously shown pro-
tective effects in the form of associations with lower VL
in a mixed population [21], we did not observe such an
effect on VL in Zambians with either haplotype overall
or with any specific diplotypes containing either of
them.
In prior studies, HHF*2 has shown somewhat incon-
sistent associations with VL and disease control
[11,17,19,20,22,23]. In our Zambian study population
HHF*2 showed a weak association with lower VL in
both index partners (b = -0.21, log10 P = 0.024) and ser-
oconverters (b = -0.10, log10 P = 0.089). When the
index partners and seroconverters were stratified by
HHF*2 genotype, a stronger association in the latter
group was largely attributable to HHF*2 homozygosity
(b = -0.70, log10 P = 0.007) (Table 3).
Both HHD and HHE have been associated with higher
VL in several studies [11,13,18,24,25]. In our Zambian
cohort, dominant models, including each haplotype plus
non-genetic factors analyzed by GLM, indicated that
HHD was associated with higher VL (b = 0.24, log10 P =
0.021) in the seroconverters, but a modest effect in the
opposite direction was observed in index partners. HHE
showed a trend toward association with higher VL in
index partners and a similar non-significant association
with higher VL in seroconverters adjusted for age and
gender (Table 3). Because this pattern of association
could be explained by combinations of haplotypes car-
ried, we explored the effect of diplotypes further.
Among all diplotypes of frequency > 0.05, HHD/HHE
showed the strongest association with higher VL (b =
0.49, log10 P = 0.02)
We next constructed a multivariable model with all
the haplotypes and diplotypes that showed a trend
toward association (log10 P < 0.10) with higher or lower
VL in either index partners or seroconverters to test
their independent influences on VL (Table 3). In this
model, by including uninformative diplotypes (HHD/
HHF*2 and HHE/HHF*2) in the reference group, each
diplotype implicated could be tested independently of
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association with higher VL. In seroconverters the HHD/
HHE and HHF*2/HHF*2 diplotypes remained signifi-
cantly and independently associated with VL after con-
trolling for individual haplotype effects (Table 3).
CCR2-CCR5 determinants of transmission from index
partners and of seroconversion in HESNs
The few studies that have attempted to assess the role
of the receptor polymorphism in transmission and
susceptibility have shown rather diverse associations of
common CCR5 haplotypes, without any discernible pat-
tern (See Additional File 1, Table S1). No SNP or haplo-
type carried by Zambian index partners was significantly
associated with transmission (data not shown). In the
survival analysis, HESNs with the HHD/HHE diplotypes
showed significantly more rapid seroconversion than
HESNs with other haplotypes (Table 4 and Figure 1a)
after adjustments for index partner VL and the presence
of genital ulcer or inflammation in either partner.
Table 1 Demographic, epidemiologic and virologic characteristics of the HIV-1 nontransmission and transmission
serodiscordant Zambian couples
Nontransmission couples Transmission couples P
Characteristic
Number of couples 327 240
Male/Female (index partner) 148/179 147/93 0.0002
Age of partners (yrs)
Index 31.5 ± 7.9 30.6 ± 7.8 0.170
Exposed 32.0 ± 8.3 28.6 ± 7.3 < 0.0001
Follow-up time (median [IQR], months) 31.5 [17.0-56.1] 17.7 [8.8-36.2] < 0.0001
Male circumcised
Index 8.8% 9.0% 0.970
Exposed 19.5% 9.9% 0.053
Genital ulcers
Index 12.8% 36.6% < 0.0001
Exposed 4.1% 26.3% < 0.0001
Genital inflammation
a
Index 10.3% 26.3% < 0.0001
Exposed 6.6% 29.1% < 0.0001
Any sexually transmitted disease
Index 20.7% 50.2% < 0.0001
Exposed 10.0% 46.0% < 0.0001
HIV-1 RNA level (log10) in index partner 4.47 ± 0.90 4.96 ± 0.70 < 0.0001
HIV-1 RNA level (log10) in seroconverted partner 4.50 ± 0.80 NA
aIn the 3-6 months before HIV-1 transmission (transmission couples) or latest follow-up visit (nontransmission couples).
Table 2 Frequencies of CCR2-CCR5 polymorphisms among HIV-1 serodiscordant couples, index partners, and HIV-1
exposed seronegative partners
HESN
a partners
All (N = 1134) Index partners (N = 567) All (N = 567) Seroconverters (N = 240) Uninfected (N = 327)
Haplotype N (%) N (%) N (%) N (%) N (%)
HHA 601 (26.5) 305 (26.9) 296 (26.1) 133 (27.7) 163 (24.9)
HHB 44 (1.9) 25 (2.2) 19 (1.7) 8 (1.7) 11 (1.7)
HHC 178 (7.9) 69 (6.1) 109 (9.6) 42 (8.8) 67 (10.2)
HHD 370 (16.3 190 (16.8) 180 (15.9) 75 (15.6) 105 (16.1)
HHE 310 (13.7) 138 (12.2) 172 (15.2) 61 (12.7) 111 (17.0)
HHF*1 128 (5.6) 76 (6.7) 52 (4.6) 24 (5.0) 28 (4.3)
HHF*2 480 (21.2) 259 (22.8) 221 (19.5) 99 (20.6) 122 (18.7)
HHG*1 157 (6.9) 72 (6.4) 85 (7.5) 38 (7.9) 47 (7.2)
HWE:P
b 0.0001 0.0001 0.267 0.024 0.160
aHESN = HIV-1 exposed seronegative.
bP values for tests of Hardy-Weinberg equilibrium in each of the patient groups.
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association with faster HIV-1 acquisition, we assigned it
to a separate stratum in the Kaplan-Meier plot because
aggregating it in the reference group would have given
the appearance of a weaker HHD/HHE effect (Multi-
variable Cox model HR = 2.0, 95% CI = 1.20-3.43, P =
0.008). Stratification by gender revealed a stronger
impact of HHD/HHE on HESN women than men
(Table 4 and Figure 1b) (Multivariable Cox model HR =
2.1, 95% CI = 1.14-3.95, P = 0.018).
Discussion
Many investigations into genetic determinants of HIV/
AIDS have evaluated the effects of Δ32, selected SNPs,
and haplotypes across CCR2-CCR5 on disease progres-
sion in a variety of infected populations. Studies of these
m a r k e r sa sd e t e r m i n a n t so fa c q u i s i t i o nh a v eu s u a l l y
been conducted in pairs of mothers and infants or in
exposed men of European ancestry whose male sexual
contacts are largely unknown [13,17,25-27]. Our rela-
tively large prospective study of heterosexual discordant
Table 3 The impact of CCR2-CCR5 haplotypes on HIV-1 viral load in Zambian index partners and seroconverters
Index partners Recent seroconverters
(N = 567) (N = 240)
Viral Load Table for CCR5 haplotype/diplotype
Haplotype/diplotype N b ±S E
a P* N b ±S E
a P*
HHF*2 232 -0.21 ± 0.09 0.024 89 -0.10 ± 0.58 0.089
HHF*2/HHF*2 27 -0.08 ± 0.16 0.625 10 -0.70 ± 0.26 0.007
HHD (All) 164 -0.12 ± 0.06 0.052 69 0.24 ± 0.10 0.021
HHE (All) 131 0.13 ± 0.08 0.096 61 0.12 ± 0.12 0.339
HHD/HHE 18 -0.22 ± 0.20 0.270 16 0.49 ± 0.21 0.020
HHD/X (No HHE) 146 -0.11 ± 0.08 0.157 53 0.14 ± 0.13 0.284
HHE/X (No HHD) 113 0.19 ± 0.09 0.026 45 -0.06 ± 0.13 0.673
Multivariable Model for Interaction**
Haplotype/diplotype N b ±S E
a P* N b ±S E
a P*
HHD/X (No HHE or HHF*2) 109 -0.16 ± 0.09 0.560 37 0.24 ± 0.16 0.118
HHE/X (No HHD or HHF*2) 69 0.36 ± 0.11 0.002 31 0.10 ± 0.16 0.556
HHD/HHE 18 -0.16 ± 0.20 0.444 16 0.54 ± 0.22 0.014
HHF*2/HHF*2 27 -0.02 ± 0.16 0.918 10 -0.58 ± 0.26 0.027
HHF2/X (No HHD, HHE or HHF*2) 124 0.05 ± 0.09 0.602 49 0.10 ± 0.14 0.496
aSE, standard error of the b estimate according to linear regression models.
*P value adjusted for the sex and age at VL for all the individuals.
**Individuals with HHD/HHF*2, HHE/HHF*2 diplotypes are in the reference group in the multivariable model for interaction.
Table 4 Proportional hazards analysis of the effect of CCR2-CCR5 haplotype or diplotype on HIV-1 acquisition.
Overall Male-to-Female Female-to-Male
(567 couples) (295 couples) (272 couples)
Cox model for individual CCR2-CCR5 haplotype or diplotype.
Haplotype/diplotype N* HR 95% CI P** N* HR 95% CI P** N* HR 95% CI P**
HHF*2 203 1.1 0.85-1.46 0.417 104 1.1 0.77-1.56 0.61 99 1.2 0.75-1.75 0.531
HHD 167 1.0 0.74-1.32 0.983 94 0.9 0.59-1.23 0.385 73 1.2 0.75-1.92 0.442
HHE 158 1.1 0.82-1.51 0.495 85 1.3 0.86-1.87 0.234 73 0.9 0.57-1.53 0.781
HHD/HHE 31 1.9 1.14-3.16 0.015 19 2.0 1.08-3.57 0.028 12 1.7 0.60-4.66 0.321
Multivariable model for CCR2-CCR5 HHD/HHE diplotype and HHF*2 haplotype.
Genetic factors N* HR 95% CI P** N* HR 95% CI P** N* HR 95% CI P**
HHD/HHE 31 2.0 1.20-3.43 0.008 19 2.1 1.14-3.95 0.018 12 1.8 0.64-5.08 0.267
HHF*2 203 1.2 0.90-1.57 0.222 104 1.2 0.83-1.72 0.337 99 1.2 0.77-1.82 0.439
Any genital ulcer or inflammation 299 3.6 2.65-4.93 < .0001 162 3.0 2.04-4.51 < .0001 137 4.6 2.79-7.65 < .0001
Donor VL (per 1.0 log10 unit) 523 1.6 1.32-1.91 < .0001 263 1.3 1.03-1.74 0.028 260 1.8 1.35-2.47 < .0001
*N represents the number of HESNs with each genotype.
**P values adjusted for genital ulcer, genital inflammation in either partner, and index partner log10 VL.
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vement of variants in these genes in both control and
occurrence of HIV-1 infection.
HHE was associated with slightly higher VL than was
seen with other haplotypes, a finding consistent with
observations in a number of other studies on different
ethnic groups and various modes of transmission
[11,17,28,29]. Further confirmation of the effect of HHE
highlights its potential impact on clinical HIV-1 disease
control in diverse populations, in contrast to that of the
protective Δ32 variant whose distribution is confined to
individuals of European ancestry. We detected an asso-
ciation of homozygous HHF*2 (containing CCR2-64I)
with lower VL in recent seroconverters but found less
certain effects of heterozygous HHF*2. This finding is
consistent with previous reports [11,17,19,20,22].
Although an early meta-analysis persuasively documen-
ted modest protection by the 64I allele against progres-
sion of HIV-1 subtype B infection [22], results in
subsequent studies have been less consistent–showing
association with slow progression either among Eur-
opeans, but not African-Americans [19,20] or among
African-Americans but not Europeans [23,29]. For
populations with subtype C infection, however, no pre-
vious study is available as a basis for comparison.
As for the influence of CCR2-CCR5 alleles or haplo-
types on transmission and acquisition of infection, the
highly significant deviation of the distribution of haplo-
types from HWE among the index, but not the exposed
partners, was strong evidence of a selective effect, and
the differential deviation of the seroconverters, but not
the persistently seronegatives, corroborated the differ-
ence. Neither chance nor systematic selection of couples
into the study cohort by their CCR2-CCR5 profile
unrelated to infection seems as plausible an explanation
as the direct effect on acquisition of HIV-1 infection
proposed here.
No CCR2-CCR5 variant carried by index partners was
associated with an appreciab l ed i f f e r e n c ei nt r a n s m i s -
sion–not even the diplotype HHD/HHE associated with
a statistically significant higher mean VL. This relative
deviation in level of viremia was apparently not equiva-
lent to the larger deviation conferred by index partner
HLA-B*57, a genetic marker associated with a signifi-
cantly lower transmission rate in this population [14].
Such differential impact of the different genetic markers
may reflect a threshold effect by which a deviation of
VL greater than a certain level overrides any genetic
influence, but the number of subjects in our cohort was
insufficient to assess that possibility.
We observed a trend toward an increased rate of acqui-
sition among the exposed partners carrying HHF*2. In
another African population (Cameroon), the frequency of
CCR2-64I (HHF*2) was higher in the HIV-1 seropositives
(most likely of mixed viral subtype) than in the seronega-
tives [30]. However, we remain skeptical about the
importance of these findings for several reasons. First,
the association and its significance in Zambians dimin-
ished in the multivariable analysis. Second, previous evi-
dence for a role of HHF*2 in occurrence of infection is
sparse, and there is no other report from a prospective
study. Third, considerable uncertainty remains about the
functional relevance of the HHF*2 polymorphism and
CCR2 itself to HIV-1 infection [31]. Further population
studies alone are unlikely to clarify more precisely the
true nature of this genetic contribution.
More rapid HIV-1 acquisition among exposed serone-
gatives occurred in association with the HHD/HHE
Figure 1 Association of two CCR2-CCR5 diplotype (HHD/HHE and HHF*2) with time to HIV-1 acquisition among initially seronegative
partners of HIV-1 discordant Zambian couples. Analysis was based on 567 initially seronegative HESNs (panel a) or 295 seronegative female
HESNs only (panel b). Vertical lines on each Kaplan-Meier curve represent subjects censored at the last follow up visit (before December 2006).
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w o m e nt h a nm e n .A na s s o c i a t i o nw i t ht h i sd i p l o t y p e
has not been reported before, most likely because the
single SNP allele that distinguishes HHD from other
haplotypes is only frequent enough in persons of African
ancestry. The relatively higher frequency (7%) of HHD/
HHE in our population than in Caucasians or other
smaller groups of Africans may have facilitated detection
of its effect. Associations with higher risk of mother-to-
child transmission have been reported for HHD in Afri-
cans [32] and with homozygous HHD in African Ameri-
cans [33]. HHE has also been reported to be detrimental
for HIV infection as well as disease progression, but
HHD/HHE has not been studied previously as a diplo-
type. Although our findings do not constitute exact
replication of previous work, they appear to indicate
consistent effects of the two haplotypes across popula-
tions with different viral subtypes.
The effects of HHD/HHE appeared stronger in male-
to-female transmission. Differences in VL among the
donor groups did not explain this difference according
to direction of transmission. Nor did the difference
arise from any obvious difference in age or sexual
exposure of the two groups. For each subgroup strati-
fied by gender, the number of seronegative subjects
carrying these genotypes (diplotypes) was relatively
small. Analysis based on larger samples will be neces-
sary to reach a reliable conclusion about such gender-
specific associations.
One feature of our study worth noting is the advan-
tage of survival analysis of time to transmission/acquisi-
tion in detecting relationships that may be weaker in the
cross-sectional or case-control approach often used to
assess genetic influences on HIV-1 infection. Survival
methods may be more sensitive in capturing time-
dependent genetic effects on infection just as they have
been in the analysis of disease progression.
We did not adjust statistically for the number of
genetic polymorphisms tested. Rather we have empha-
sized those nominally significant associations with
CCR2-CCR5 variants that have previously been impli-
cated in HIV/AIDS and de-emphasized those whose
involvement was less predictable from earlier studies.
T h ep r e v i o u s l yd o c u m e n t e d HHE association with
higher VL [11,17,28,29] provided ample rationale for
interpreting our results as confirmatory without treating
all haplotypes as equally likely to be involved. The
impact of HHD/HHE on seroconversion was predicted
somewhat less directly by earlier work associating HHD
with a higher frequency of neonatal infection [33]. An
even more important reason why these relationships
cannot be readily dismissed as chance findings is that
they were observed in the context of significant devia-
tions from HWE of the haplotype distributions in each
of the seropositive groups but not the seronegative
group.
A consistent effect of the frequent HHE with higher
VL in subtype C HIV-1-infected Africans as well as sub-
type B-infected Europeans and a stronger effect of
HHD/HHE could have further ramifications. Since the
response to antiretroviral treatment in Europeans may
be modified by (Δ32) [34-36] and perhaps by other
receptor variants [37,38], investigators in African set-
tings should consider whether similar studies of CCR2-
CCR5 polymorphism might provide epidemiologically or
clinically useful prognostic information.
Conclusions
In summary, our analysis of CCR2-CCR5 haplotypes
consisting of common combinations of SNP alleles
spanning those two genes has confirmed a previously
reported association of haplotype HHF*2 with favorable
response to HIV-1 infection; and our longitudinal analy-
sis of seroconversion in HESN African heterosexual
partners has detected probable contributions by the
HHD/HHE diplotype to acquisition of infection
[11,17,39]. Further insight into these relationships will
be gained from studies of correlation between gene var-
iation and gene function, as well as investigation of
other representative and informative populations of
infected and uninfected Africans.
Methods
Study population
Our study population comprised HIV-1 serodiscordant,
cohabiting heterosexual couples enrolled in the Zambia-
Emory HIV Research Project between 1995 and 2006.
The procedures for screening, recruitment, counseling,
follow-up visits and laboratory testing have been
described elsewhere [15,40]. All couples whose HESN
partner acquired virologically linked HIV-1 from the
index partner during follow-up were included in this
study. For closer comparability to the transmitters, non-
transmission couples were selected from a large number
based on self-reported behavioral or clinical measures of
unprotected sex. Virologically linked HIV-1 transmission
was defined as identity between viruses from index and
seroconverting partners, according to phylogenetic ana-
lysis of sub-genomic sequences of gag, env (gp120 and
gp41), and long terminal repeat regions [16,40]. Partici-
pant characteristics have previously been thoroughly
examined as potential risk factors for transmission in
this cohort [15,16,40,41]. Risk factors considered here
include index partner (donor) viral load (VL), age of
each partner, and genital ulceration/inflammation in
each partner. The study population consisted of 567
couples with: a) adequate data and biologic material for
both partners, b) observation of nontransmission
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gic linkage when transmission occurred, and d) none of
the partners on anti-retroviral treatment.
Non-genetic factors
VL was quantified as the number of HIV-1 RNA copies
per ml of plasma using Roche Amplicor 1.0 assay (Roche
diagnostic Systems Inc., Branchburg, NJ) in a laboratory
certified by the virology quality assurance program of the
AIDS Clinical Trials Group (ACTG). The lower detection
limit was 400 copies/mL of plasma. For this work, VL
was transformed to log10 and treated as a continuous
variable. Previous analyses [40] indicated that index part-
ners with a medium number of HIV-1 RNA copies/mL
(10
4-10
5,l o g 10 = 4-5) or a high number of copies/mL (>
10
5, log10 > 5) were more likely to transmit the virus than
those with a low number (< 10
4, log10 < 4).
Genotyping
Genomic DNA was extracted from whole blood and buffy
coats using the QIAamp blood kit and protocols recom-
mended by the manufacturer (QIAGEN Inc., Valencia,
CA). PCR-based typing differentiated the dimorphic var-
iants at eight sites–one in CCR2 (the SNP encoding V64I–
rs1799864) and seven in CCR5 [six SNPs in or adjacent to
the cis-regulatory or promoter region (A29G–rs2856758,
G303A–rs1799987, T627C–rs1799988, C630T–
rs41469351, A676G–rs1800023 and C927T–rs1800024)]
and the 32-bp deletion (Δ32–rs333). CCR5 haplotypes
were typed by a combination of two methods: a PCR typ-
ing scheme and a TaqMan SNP typing scheme. The PCR
typing scheme used 12 combinations of sequence-specific
primers (SSP) plus four additional SSP reactions in con-
junction with T627C-specific primers to define the A29G
variant as described for previous work [11,13,17-20]. Com-
bination of variants at the eight sites form nine relatively
frequent CCR2-CCR5 haplotypes (HHA-HHE, HHF*1,
HHF*2, HHG*1 and HHG*2) according to the nomencla-
ture of the Tri-Service HIV-1 Natural History Study (TSS)
[42]. HHF*2 is the only haplotype carrying the V64I muta-
tion. A TaqMan genotyping assay was used to confirm the
PCR-based SNP typing and assign CCR5 haplotypes for
126 individuals. TaqMan assays were performed using
customized TaqMan probes for 7 SNP sites; SNP alleles
were assigned after real-time PCR using the ABI 7500 Fast
System (Applied Biosystems) according to procedures
recommended by the manufacturer.
Statistical analysis
Non-genetic factors (VL, age, gender, genital ulcer, geni-
tal inflammation, circumcision, and presence of sperm)
were compared between seroconverting and non-sero-
converting exposed partners using c
2 and t-tests. Hardy-
Weinberg equilibrium (HWE) for each SNP and CCR
haplotype distribution was assessed using SAS Genetics
(see below). HWE was calculated for the entire cohort
and for four separate partner groups: transmission index,
nontransmission index, seroconverting, and exposed
uninfected partners. Associations of frequent haplotypes/
genotypes with HIV-1 VL among the index partners and
seroconverters were tested using general linear model
(GLM) statistics with adjustment for age and gender.
For analysis of time-to-infection (transmission and
acquisition), follow-up time for each couple was mea-
sured from the date of their enrollment into the cohort
to 1) the date of HIV-1 infection (first seropositive visit)
of the initially uninfected exposed partner or 2) the most
recent seronegative visit prior to administrative censoring
date (December 31, 2006). Time-to-infection was dis-
played in Kaplan-Meier plots, and comparisons between
genetically distinctive groups were evaluated with Wil-
coxon and log-rank tests. These plots illustrate differ-
ences in transmission associated with specific genetic
markers; they do not reflect transmission rates in the
entire prospectively observed discordant couple popula-
tion. The overall annual HIV-1 seroincidence (7-8/100
PY) represents a one-half to two-thirds reduction in
transmission following joint testing and counseling.
Statistical analysis of genetic variants of CCR2 and
CCR5 consisted of testing hypotheses derived from ear-
lier work on acquisition or progression of infection (See
Additional File 1; Table S1) followed by systematic
search for novel associations in our study population.
Multivariable Cox proportional hazards models were
used to control for non-genetic covariates. We estimated
the hazard ratios (HR), its 95% confidence interval (CI),
and the corresponding two-sided P-values. For hypoth-
eses on genetic markers consistent with previously
reported associations, statistical testing was performed
without correction for multiple comparisons. All statisti-
cal analyses were done using SAS
® 9.2 including SAS/
Genetics™ (SAS Institute Inc., Cary, NC).
Additional material
Additional file 1: Table S1: Studies of associations between
polymorphisms in CCR2 and CCR5 and acquisition or progression of
HIV-1 infection. Summary of the recent publications on CCR2-CCR5
haplotypes and association with HIV-1 acquisition or disease progression.
Includes references [43-45]
Additional file 2: Table S2: CCR2-CCR5 haplotypes and diplotypes as
observed in HIV-1 discordant Zambian couples. Frequency of CCR2-
CCR5 haplotypes and common diplotypes in overall Zambia cohort and
subgroups. Rare diplotypes with count less than 12 in overall cohort are
not shown.
List of Abbreviations
CCR5: C-C chemokine receptor 5; CCR2: C-C chemokine receptor 2; AIDS:
acquired immunodeficiency syndrome; HIV: human immunodeficiency virus;
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equilibrium; HHA, etc: human haplotype A, etc.
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